Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

AB-928 is an adenosine A2A and A2B receptor dual antagonist.1 It inhibits the ability of adenosine (Item No. 21232) to suppress activation of human CD4 or CD8 T cells, as well as monocyte-derived dendritic cells, in vitro.2,3 AB-928, alone or in combination with doxorubicin (Item No. 15007), reduces tumor growth in an AT3-OVA syngeneic mouse model. It also acts synergistically with an anti-PD-1 antibody to reduce tumor growth in a B16/F10 syngeneic mouse model.
WARNING This product is not for human or veterinary use.
1. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest. New Drugs 37(4), 711-721 (2019).
2. Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. Cancer Res. 78(13 Suppl.), (2018).
3. Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-